Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis.

about

Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by.Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritis.

P2860

Q37362082-5F4BA727-3305-4F33-8F9A-7491C6DB101D Q47696280-D5686A19-661C-4AE6-93EE-87B5A193EDD6

P2860

Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis.

Item

http://www.wikidata.org/entity/Q38669060

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Ixekizumab: a new anti-IL-17A ...... te-to severe plaque psoriasis.

@en

type

Item

label

Ixekizumab: a new anti-IL-17A ...... te-to severe plaque psoriasis.

@en

prefLabel

Ixekizumab: a new anti-IL-17A ...... te-to severe plaque psoriasis.

@en

P1476

Ixekizumab: a new anti-IL-17A ...... te-to severe plaque psoriasis.

@en

P2093

Andrew Blauvelt

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

Circulating Th17, Th22, and Th1 cells are increased in psoriasis

IL-23/IL-17A Dysfunction Phenotypes Inform Possible Clinical Effects from Anti-IL-17A Therapies

Immunology of psoriasis

The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing

IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice

The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans

P304

255-263

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.2016.1132695

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

287150118

http://www.w3.org/2001/XMLSchema#string

P698

26666707

http://www.w3.org/2001/XMLSchema#string

Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis.

about

P2860

P2860

Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698